Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Takaichi Urges Public-Private Investment Push in Drug Discovery
Japanese Prime Minister Sanae Takaichi has instructed Health Minister Kenichiro Ueno to promote public-private investments in drug discovery and advanced medicine, as part of the policy priorities for her second Cabinet. In written directives issued to all returning ministers by…
To read the full story
Related Article
- PM Vows Comprehensive Support for 17 Priority Sectors: Policy Speech
February 24, 2026
- PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
REGULATORY
- Biosimilar Efficacy Trials Can Be Waived under Certain Conditions: MHLW
May 13, 2026
- LDP Lawmakers’ League Eyes Broader Push for Domestic API Production
May 13, 2026
- AstraZeneca’s Oral SERD, MSD RSV Antibody Up for Japan Panel Review on May 25
May 12, 2026
- Daiichi Sankyo Wins Japan Approval for MMR Vaccine Mimrit
May 12, 2026
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…